An Open Label Study to Evaluate the Safety and Efficacy of 12 Week Treatment With CFZ533 in Patients With Graves' Disease

Trial Profile

An Open Label Study to Evaluate the Safety and Efficacy of 12 Week Treatment With CFZ533 in Patients With Graves' Disease

Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Mar 2017

At a glance

  • Drugs CFZ 533 (Primary)
  • Indications Graves' disease
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 14 Mar 2017 Planned End Date changed from 1 Apr 2017 to 2 May 2017.
    • 14 Mar 2017 Planned primary completion date changed from 1 Apr 2017 to 2 May 2017.
    • 10 Nov 2016 Planned End Date changed from 1 May 2017 to 1 Apr 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top